Physician profile
Clay J Cockerell
NPI 1235119298
$39,557.63
in general payments reported to CMS, 2019-2025
28 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,559 · 2020: $5,116 · 2021: $8,686 · 2022: $683 · 2023: $1,401 · 2024: $1,366 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,320 · Food and Beverage: $4,723 · Honoraria: $2,870 · Travel and Lodging: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,320.00 |
| Food and Beverage | $4,723.30 |
| Honoraria | $2,870.00 |
| Travel and Lodging | $1,600.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $16,045.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $10,193.37 | 2025 | |
| Stemline Therapeutics INC. | $3,825.00 | 2021 | |
| Blueprint Medicines Corporation | $2,998.78 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $634.94 | 2019-2024 | Arazlo, Siliq, Zyclara |
| Arcutis Biotherapeutics, INC. | $547.85 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $475.42 | 2020-2025 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.60 | 2023-2025 | Spevigo |
| Genzyme Corporation | $460.55 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $419.13 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $335.08 | 2019-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $287.52 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $282.19 | 2019-2022 | |
| Incyte Corporation | $281.43 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $271.20 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $266.97 | 2023-2025 | Tremfya |
| Ucb, INC. | $252.57 | 2024-2025 | Bimzelx |
| Sensus Healthcare, INC. | $251.96 | 2019-2020 | |
| Lilly USA, LLC | $240.91 | 2019-2022 | |
| Galderma Laboratories, L.P. | $150.44 | 2019-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $146.31 | 2025 | Tremfya |
| Biofrontera INC. | $140.52 | 2019 | |
| Abbvie INC. | $124.56 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.57 | 2025 | Siliq |
| Amgen INC. | $108.29 | 2022 | |
| Pfizer INC. | $107.24 | 2019 | |
| Kyowa Kirin, INC. | $91.60 | 2024 | Poteligeo |
| Epi Health, LLC | $32.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Cockerell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.